≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Burn and corrosion of other internal organs

Endpoint Browser

ST19_BURN_CORROSION_OTHER_INTERNAL_ORGANS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — T28
  • Cause of death: ICD-10 — T28

2 out of 7 registries used, show all original rules.

120

4. Check minimum number of events

None

120

5. Include endpoints

None

120

6. Filter based on genotype QC (FinnGen only)

118

Control definitions (FinnGen only)

Control exclude
CD2_BENIGN_FEMALE_GEN_OTH

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
T2[6-8]
Name in latin
Combustiones et corrosiones ahiorum organorum internorum

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 118 57 61
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 44.12 40.41 47.60

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
120
Matched controls
1200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
T28.6
ICD-10 Finland
Corrosion of oesophagus
+∞
65.8
57
*
T28.5
ICD-10 Finland
Corrosion of mouth and pharynx
+∞
36.3
33
*
T36
ICD-10 Finland
Poisoning by systemic antibiotics
14.4
28.7
29
26
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
28.5
25.8
35
17
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.7
24.8
69
201
X49
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified chemicals and noxious substances
296.8
24.6
24
*
T28.0
ICD-10 Finland
Burn of mouth and pharynx
+∞
18.2
17
*
F32.9
ICD-10 Finland
Depressive episode, unspecified
5.6
16.1
39
95
T54.3
ICD-10 Finland
Toxic effect: Corrosive alkalis and alkali-like substances
+∞
16.0
15
*
WX892
NOMESCO Finland
Monitored bed care
8.1
15.5
23
34
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.5
14.9
36
87
N05AH04
ATC
quetiapine; oral
4.6
14.2
47
147
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
6.4
14.2
27
52
N05AH03
ATC
olanzapine; systemic
6.4
13.7
26
50
K22.2
ICD-10 Finland
Oesophageal obstruction
56.6
13.2
15
*
N05AF03
ATC
chlorprothixene; systemic
20.9
12.5
18
10
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.9
12.2
33
87
N05BA04
ATC
oxazepam; oral
3.9
11.5
50
187
N03AG01
ATC
valproic acid; systemic, rectal
6.0
10.8
21
41
X59
ICD-10 Finland
Exposure to unspecified factor
3.9
10.6
42
146
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
5.5
10.2
22
47
N05AX08
ATC
risperidone; systemic
4.8
10.1
26
65
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
28.8
10.0
13
5
ZXD05
NOMESCO Finland
Urgent procedure
3.4
9.9
53
224
AA1AD
NOMESCO Finland
CT of head and brain
3.5
9.5
47
188
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
5.3
9.5
21
46
UJC12
NOMESCO Finland
Flexible oesophagoscopy
40.0
9.2
11
*
N03AX16
ATC
[U] pregabalin
3.5
8.8
39
145
JDB10
NOMESCO Finland
Percutaneous gastrostomy
30.0
8.6
11
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.4
8.4
18
38
N06AX11
ATC
mirtazapine; oral
3.0
8.3
60
297
S01.0
ICD-10 Finland
Open wound of scalp
5.1
8.2
19
43
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
24.0
8.2
11
5
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
12.0
8.0
14
13
N05BA01
ATC
diazepam; systemic, rectal
3.8
7.7
27
85
A02BC05
ATC
esomeprazole; systemic
2.9
7.7
62
322
S06.0
ICD-10 Finland
Concussion
4.0
7.4
24
71
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
17.1
7.4
11
7
T28.3
ICD-10 Finland
Burn of internal genitourinary organs
+∞
7.4
7
*
Z91.5
ICD-10 Finland
Personal history of self-harm
+∞
7.4
7
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.9
7.1
24
73
N07BB01
ATC
disulfiram; oral
6.6
6.9
17
29
A02BC02
ATC
pantoprazole; systemic
3.1
6.9
91
602
N05CF01
ATC
zopiclone; oral
2.8
6.7
48
230
X58
ICD-10 Finland
Exposure to other specified factors
3.3
6.7
30
110
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
13.3
6.7
11
9
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
3.9
6.7
22
66
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
6.2
6.6
17
31
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
9.0
6.5
13
16
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
15.4
6.5
10
7
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
12.0
6.4
11
10
TJD20
NOMESCO Finland
Change of gastrostomy tube
+∞
6.3
6
*
WX872
NOMESCO Finland
Intensive care
7.4
6.2
14
21
F99
ICD-10 Finland
Mental disorder, not otherwise specified
13.5
6.2
10
8
Z53.2
ICD-10 Finland
Procedure not carried out because of patient's decision for other and unspecified reasons
16.1
6.0
9
6
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
16.1
6.0
9
6
F60.9
ICD-10 Finland
Personality disorder, unspecified
16.1
6.0
9
6

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Psychiatry
26 [38004469]
1.9e+00
1.9e+00
2.3e+00
—
3.1e+00
2.6e+00
2.0e+00
cases:25.00%
controls:4.74%
cases:18.97%
controls:3.53%
cases:12.07%
controls:1.38%
—
—
cases:14.66%
controls:0.78%
cases:24.77%
controls:2.39%
cases:36.19%
controls:6.88%
29
55
87
1105
22
41
94
1119
14
16
102
1144
—
17
9
99
1147
27
27
82
1102
38
74
67
1001
Inpatient Hospital
21 [8717]
9.9e-01
1.5e+00
2.6e+00
1.0e+50
3.5e+00
1.7e+00
1.1e+00
cases:53.45%
controls:29.91%
cases:34.48%
controls:10.69%
cases:12.93%
controls:1.12%
cases:50.00%
controls:0.00%
cases:20.69%
controls:0.78%
cases:33.94%
controls:8.77%
cases:52.38%
controls:26.23%
62
347
54
813
40
124
76
1036
15
13
101
1147
58
0
58
1160
24
9
92
1147
37
99
72
1030
55
282
50
793
quetiapine; oral
N05AH04 [21604544]
1.8e+00
2.3e+00
—
—
2.5e+00
2.3e+00
2.2e+00
cases:17.24%
controls:3.19%
cases:15.52%
controls:1.72%
—
—
—
—
cases:6.90%
controls:0.61%
cases:15.60%
controls:1.77%
cases:21.90%
controls:3.16%
20
37
96
1123
18
20
98
1140
—
—
8
7
108
1149
17
20
92
1109
23
34
82
1041
Outpatient Hospital
22 [8756]
7.1e-01
1.1e+00
2.4e+00
1.0e+50
3.4e+00
1.7e+00
1.0e+00
cases:37.07%
controls:22.50%
cases:18.97%
controls:7.07%
cases:6.90%
controls:0.69%
cases:28.45%
controls:0.00%
cases:11.21%
controls:0.43%
cases:22.02%
controls:5.14%
cases:39.05%
controls:18.51%
43
261
73
899
22
82
94
1078
8
8
108
1152
33
0
83
1160
13
5
103
1151
24
58
85
1071
41
199
64
876
Emergency Room Visit
ER [9203]
7.8e-01
1.3e+00
2.5e+00
—
2.5e+00
1.6e+00
1.3e+00
cases:49.14%
controls:30.69%
cases:32.76%
controls:11.81%
cases:19.83%
controls:1.90%
—
—
cases:12.93%
controls:1.21%
cases:38.53%
controls:11.25%
cases:65.71%
controls:35.16%
57
356
59
804
38
137
78
1023
23
22
93
1138
—
15
14
101
1142
42
127
67
1002
69
378
36
697
General Practice
1 [38004446]
1.2e+00
1.9e+00
2.0e+00
1.0e+50
2.2e+00
1.2e+00
9.3e-01
cases:30.17%
controls:11.64%
cases:25.00%
controls:4.74%
cases:6.03%
controls:0.86%
cases:7.76%
controls:0.00%
cases:5.17%
controls:0.61%
cases:15.60%
controls:5.05%
cases:28.57%
controls:13.58%
35
135
81
1025
29
55
87
1105
7
10
109
1150
9
0
107
1160
6
7
110
1149
17
57
92
1072
30
146
75
929
olanzapine; oral, parenteral
N05AH03 [21604543]
2.0e+00
2.0e+00
—
—
—
2.8e+00
2.4e+00
cases:6.90%
controls:1.03%
cases:6.90%
controls:0.95%
—
—
—
—
—
—
cases:11.93%
controls:0.80%
cases:12.38%
controls:1.21%
8
12
108
1148
8
11
108
1149
—
—
—
13
9
96
1120
13
13
92
1062
levomepromazine; oral, parenteral
N05AA02 [21604493]
2.3e+00
2.4e+00
—
—
—
—
2.8e+00
cases:5.17%
controls:0.52%
cases:6.03%
controls:0.60%
—
—
—
—
—
—
—
—
cases:8.57%
controls:0.56%
6
6
110
1154
7
7
109
1153
—
—
—
—
9
6
96
1069
INR in Blood by Coagulation assay
34714-6 [3032080]
7.6e-01
1.0e+00
1.8e+00
—
2.5e+00
1.6e+00
1.4e+00
cases:9.48%
controls:4.66%
cases:9.48%
controls:3.53%
cases:6.03%
controls:1.03%
—
—
cases:8.62%
controls:0.78%
cases:12.84%
controls:2.83%
cases:25.71%
controls:8.09%
11
54
105
1106
11
41
105
1119
7
12
109
1148
—
10
9
106
1147
14
32
95
1097
27
87
78
988
Emergency Medicine
93 [38004510]
5.9e-01
1.2e+00
2.0e+00
—
2.4e+00
1.0e+00
9.4e-01
cases:12.07%
controls:7.07%
cases:14.66%
controls:4.91%
cases:7.76%
controls:1.12%
—
—
cases:7.76%
controls:0.78%
cases:13.76%
controls:5.49%
cases:33.33%
controls:16.28%
14
82
102
1078
17
57
99
1103
9
13
107
1147
—
9
9
107
1147
15
62
94
1067
35
175
70
900
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
5.6e-01
1.2e+00
2.2e+00
—
2.7e+00
1.4e+00
1.1e+00
cases:10.34%
controls:6.21%
cases:11.21%
controls:3.71%
cases:4.31%
controls:0.52%
—
—
cases:8.62%
controls:0.61%
cases:11.01%
controls:2.83%
cases:27.62%
controls:11.44%
12
72
104
1088
13
43
103
1117
5
6
111
1154
—
10
7
106
1149
12
32
97
1097
29
123
76
952
Depressive episode, unspecified
F32.9 [45571760]
1.9e+00
2.2e+00
—
—
—
1.9e+00
2.1e+00
cases:12.07%
controls:1.98%
cases:6.03%
controls:0.69%
—
—
—
—
—
—
cases:5.50%
controls:0.89%
cases:16.19%
controls:2.33%
14
23
102
1137
7
8
109
1152
—
—
—
6
10
103
1119
17
25
88
1050
Upper gastrointestinal surgery
106 [44777669]
4.8e-01
7.5e-01
—
1.0e+50
3.7e+00
2.5e+00
8.7e-01
cases:10.34%
controls:6.64%
cases:5.17%
controls:2.50%
—
—
cases:23.28%
controls:0.00%
cases:14.66%
controls:0.43%
cases:15.60%
controls:1.51%
cases:18.10%
controls:8.47%
12
77
104
1083
6
29
110
1131
—
27
0
89
1160
17
5
99
1151
17
17
92
1112
19
91
86
984
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.9e+00
1.9e+00
—
—
—
2.1e+00
2.1e+00
cases:11.21%
controls:1.81%
cases:5.17%
controls:0.78%
—
—
—
—
—
—
cases:7.34%
controls:0.97%
cases:11.43%
controls:1.58%
13
21
103
1139
6
9
110
1151
—
—
—
8
11
101
1118
12
17
93
1058
Internal Medicine
11 [38004456]
8.2e-01
1.1e+00
2.1e+00
1.0e+50
1.2e+00
1.0e+00
8.3e-01
cases:35.34%
controls:19.48%
cases:23.28%
controls:9.05%
cases:10.34%
controls:1.38%
cases:8.62%
controls:0.00%
cases:4.31%
controls:1.38%
cases:19.27%
controls:7.79%
cases:36.19%
controls:19.91%
41
226
75
934
27
105
89
1055
12
16
104
1144
10
0
106
1160
5
16
111
1140
21
88
88
1041
38
214
67
861
Outpatient Visit
OP [9202]
2.5e-01
3.6e-01
9.8e-01
2.3e+00
1.4e+00
1.2e+00
7.5e-01
cases:66.38%
controls:60.60%
cases:49.14%
controls:40.26%
cases:22.41%
controls:9.74%
cases:11.21%
controls:1.21%
cases:28.45%
controls:9.34%
cases:67.89%
controls:38.44%
cases:84.76%
controls:72.37%
77
703
39
457
57
467
59
693
26
113
90
1047
13
14
103
1146
33
108
83
1048
74
434
35
695
89
778
16
297
esomeprazole; oral, parenteral
A02BC05 [21600100]
7.9e-01
6.5e-01
—
—
3.2e+00
1.4e+00
1.1e+00
cases:11.21%
controls:5.43%
cases:6.90%
controls:3.71%
—
—
—
—
cases:9.48%
controls:0.43%
cases:11.93%
controls:3.19%
cases:19.05%
controls:7.26%
13
63
103
1097
8
43
108
1117
—
—
11
5
105
1151
13
36
96
1093
20
78
85
997
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
2.8e+00
—
—
1.0e+50
1.0e+50
—
2.7e+00
cases:9.48%
controls:0.60%
—
—
—
—
cases:18.97%
controls:0.00%
cases:12.07%
controls:0.00%
—
—
cases:10.48%
controls:0.74%
11
7
105
1153
—
—
22
0
94
1160
14
0
102
1156
—
11
8
94
1067
Poisoning by systemic antibiotics
T36 [45756588]
2.9e+00
—
—
—
—
—
2.6e+00
cases:11.21%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
cases:10.48%
controls:0.84%
13
8
103
1152
—
—
—
—
—
11
9
94
1066
temazepam; oral
N05CD07 [21604642]
1.9e+00
1.9e+00
—
—
—
1.1e+00
1.5e+00
cases:14.66%
controls:2.41%
cases:7.76%
controls:1.29%
—
—
—
—
—
—
cases:5.50%
controls:1.95%
cases:10.48%
controls:2.60%
17
28
99
1132
9
15
107
1145
—
—
—
6
22
103
1107
11
28
94
1047
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
2.5e+00
—
—
—
—
—
2.6e+00
cases:10.34%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:11.43%
controls:0.93%
12
11
104
1149
—
—
—
—
—
12
10
93
1065
Laboratory Visit
OMOP4822461 [32036]
-2.0e-02
3.7e-01
7.6e-01
3.6e+00
1.4e+00
3.4e-01
8.3e-02
cases:21.55%
controls:21.90%
cases:30.17%
controls:23.02%
cases:14.66%
controls:7.41%
cases:20.69%
controls:0.69%
cases:25.86%
controls:7.70%
cases:31.19%
controls:24.36%
cases:49.52%
controls:47.44%
25
254
91
906
35
267
81
893
17
86
99
1074
24
8
92
1152
30
89
86
1067
34
275
75
854
52
510
53
565
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.5e-01
8.0e-01
1.6e+00
—
2.4e+00
8.8e-01
6.1e-01
cases:18.10%
controls:14.66%
cases:22.41%
controls:11.47%
cases:11.21%
controls:2.59%
—
—
cases:20.69%
controls:2.34%
cases:23.85%
controls:11.51%
cases:43.81%
controls:29.86%
21
170
95
990
26
133
90
1027
13
30
103
1130
—
24
27
92
1129
26
130
83
999
46
321
59
754
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
2.2e+00
2.3e+00
—
—
—
—
2.4e+00
cases:4.31%
controls:0.52%
cases:5.17%
controls:0.52%
—
—
—
—
—
—
—
—
cases:7.62%
controls:0.74%
5
6
111
1154
6
6
110
1154
—
—
—
—
8
8
97
1067
Office Visit
OMOP4822458 [581477]
1.5e+00
1.2e+00
—
1.0e+50
—
1.9e+00
1.2e+00
cases:25.00%
controls:6.98%
cases:7.76%
controls:2.59%
—
—
cases:8.62%
controls:0.00%
—
—
cases:17.43%
controls:3.19%
cases:22.86%
controls:7.91%
29
81
87
1079
9
30
107
1130
—
10
0
106
1160
—
19
36
90
1093
24
85
81
990
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
2.2e+00
—
—
—
—
—
2.4e+00
cases:8.62%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.47%
10
12
106
1148
—
—
—
—
—
5
5
100
1070
General Surgery
2 [38004447]
5.6e-01
4.2e-01
1.7e+00
—
2.2e+00
1.3e+00
9.5e-01
cases:25.86%
controls:16.55%
cases:7.76%
controls:5.26%
cases:6.03%
controls:1.12%
—
—
cases:6.90%
controls:0.78%
cases:17.43%
controls:5.23%
cases:33.33%
controls:16.19%
30
192
86
968
9
61
107
1099
7
13
109
1147
—
8
9
108
1147
19
59
90
1070
35
174
70
901
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.4e-01
8.8e-01
1.4e+00
—
2.2e+00
7.2e-01
4.6e-01
cases:18.97%
controls:15.60%
cases:28.45%
controls:14.14%
cases:10.34%
controls:2.67%
—
—
cases:21.55%
controls:3.03%
cases:25.69%
controls:14.35%
cases:42.86%
controls:32.19%
22
181
94
979
33
164
83
996
12
31
104
1129
—
25
35
91
1121
28
162
81
967
45
346
60
729
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.5e-01
4.7e-01
—
—
2.3e+00
1.1e+00
8.5e-01
cases:16.38%
controls:11.12%
cases:9.48%
controls:6.12%
—
—
—
—
cases:15.52%
controls:1.73%
cases:18.35%
controls:7.00%
cases:29.52%
controls:15.16%
19
129
97
1031
11
71
105
1089
—
—
18
20
98
1136
20
79
89
1050
31
163
74
912
mirtazapine; oral
N06AX11 [21604740]
1.5e+00
8.8e-01
—
—
—
1.4e+00
1.4e+00
cases:16.38%
controls:4.14%
cases:6.03%
controls:2.59%
—
—
—
—
—
—
cases:10.09%
controls:2.75%
cases:20.00%
controls:6.05%
19
48
97
1112
7
30
109
1130
—
—
—
11
31
98
1098
21
65
84
1010
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
—
—
—
—
2.7e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:0.44%
cases:10.48%
controls:2.51%
—
—
—
—
—
7
5
102
1124
11
27
94
1048
Urgent procedure
ZXD05 [2001311386]
1.1e+00
—
—
1.0e+50
—
2.8e+00
1.2e+00
cases:8.62%
controls:3.10%
—
—
—
—
cases:11.21%
controls:0.00%
—
—
cases:8.26%
controls:0.53%
cases:13.33%
controls:4.37%
10
36
106
1124
—
—
13
0
103
1160
—
9
6
100
1123
14
47
91
1028
Malaise and fatigue
R53 [45553741]
1.8e+00
2.2e+00
—
—
—
—
5.6e-01
cases:6.90%
controls:1.21%
cases:5.17%
controls:0.60%
—
—
—
—
—
—
—
—
cases:5.71%
controls:3.35%
8
14
108
1146
6
7
110
1153
—
—
—
—
6
36
99
1039
Neurology
13 [38004458]
1.3e+00
8.3e-01
—
—
—
1.6e+00
1.1e+00
cases:22.41%
controls:7.41%
cases:7.76%
controls:3.53%
—
—
—
—
—
—
cases:14.68%
controls:3.28%
cases:21.90%
controls:8.74%
26
86
90
1074
9
41
107
1119
—
—
—
16
37
93
1092
23
94
82
981
citalopram; oral, parenteral
N06AB04 [21604712]
9.3e-01
1.5e+00
—
—
—
1.9e+00
2.0e+00
cases:6.90%
controls:2.84%
cases:5.17%
controls:1.21%
—
—
—
—
—
—
cases:6.42%
controls:1.06%
cases:11.43%
controls:1.67%
8
33
108
1127
6
14
110
1146
—
—
—
7
12
102
1117
12
18
93
1057
CBC panel - Blood by Automated count
58410-2 [40761511]
1.7e-01
7.6e-01
1.4e+00
—
2.3e+00
7.7e-01
3.5e-01
cases:18.10%
controls:15.69%
cases:23.28%
controls:12.41%
cases:10.34%
controls:2.67%
—
—
cases:20.69%
controls:2.51%
cases:24.77%
controls:13.29%
cases:41.90%
controls:33.77%
21
182
95
978
27
144
89
1016
12
31
104
1129
—
24
29
92
1127
27
150
82
979
44
363
61
712
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
1.0e+50
—
2.1e+00
1.6e+00
—
—
—
—
—
—
cases:8.62%
controls:0.00%
—
—
cases:7.34%
controls:0.97%
cases:18.10%
controls:4.28%
—
—
—
10
0
106
1160
—
8
11
101
1118
19
46
86
1029
Pharmacy visit
OMOP4822462 [581458]
4.2e-01
4.0e-01
6.9e-01
1.9e+00
1.1e+00
6.9e-01
4.4e-01
cases:93.97%
controls:91.12%
cases:83.62%
controls:77.33%
cases:54.31%
controls:37.24%
cases:12.93%
controls:2.24%
cases:64.66%
controls:38.06%
cases:88.07%
controls:78.74%
cases:97.14%
controls:95.63%
109
1057
7
103
97
897
19
263
63
432
53
728
15
26
101
1134
75
440
41
716
96
889
13
240
102
1028
3
47
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-1.7e-02
5.5e-01
1.4e+00
—
2.1e+00
7.9e-01
2.6e-01
cases:11.21%
controls:11.38%
cases:16.38%
controls:10.17%
cases:8.62%
controls:2.24%
—
—
cases:17.24%
controls:2.42%
cases:21.10%
controls:10.81%
cases:32.38%
controls:26.88%
13
132
103
1028
19
118
97
1042
10
26
106
1134
—
20
28
96
1128
23
122
86
1007
34
289
71
786
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.1e+00
1.6e+00
—
1.0e+50
—
3.5e+00
5.9e-01
cases:7.76%
controls:2.67%
cases:4.31%
controls:0.86%
—
—
cases:21.55%
controls:0.00%
—
—
cases:15.60%
controls:0.53%
cases:8.57%
controls:4.93%
9
31
107
1129
5
10
111
1150
—
25
0
91
1160
—
17
6
92
1123
9
53
96
1022
melatonin; oral
N05CH01 [21604659]
1.9e+00
1.5e+00
—
—
—
—
1.6e+00
cases:6.03%
controls:0.95%
cases:4.31%
controls:1.03%
—
—
—
—
—
—
—
—
cases:12.38%
controls:2.70%
7
11
109
1149
5
12
111
1148
—
—
—
—
13
29
92
1046
cefalexin; oral
J01DB01 [21602870]
5.3e-01
4.9e-01
—
—
2.7e+00
7.9e-01
7.2e-01
cases:38.79%
controls:27.24%
cases:11.21%
controls:7.16%
—
—
—
—
cases:6.03%
controls:0.43%
cases:15.60%
controls:7.71%
cases:44.76%
controls:28.19%
45
316
71
844
13
83
103
1077
—
—
7
5
109
1151
17
87
92
1042
47
303
58
772
One hour or less
ZXE00 [2001311394]
3.6e-01
—
—
1.0e+50
—
2.1e+00
1.3e+00
cases:6.90%
controls:4.91%
—
—
—
—
cases:8.62%
controls:0.00%
—
—
cases:7.34%
controls:0.97%
cases:17.14%
controls:5.40%
8
57
108
1103
—
—
10
0
106
1160
—
8
11
101
1118
18
58
87
1017
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
—
—
1.0e+50
—
2.0e+00
1.3e+00
—
—
—
—
—
—
cases:6.03%
controls:0.00%
—
—
cases:8.26%
controls:1.15%
cases:13.33%
controls:4.00%
—
—
—
7
0
109
1160
—
9
13
100
1116
14
43
91
1032
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.8e-01
6.8e-01
1.2e+00
—
2.1e+00
6.2e-01
3.7e-01
cases:19.83%
controls:17.16%
cases:27.59%
controls:16.12%
cases:11.21%
controls:3.53%
—
—
cases:22.41%
controls:3.55%
cases:26.61%
controls:16.30%
cases:44.76%
controls:36.00%
23
199
93
961
32
187
84
973
13
41
103
1119
—
26
41
90
1115
29
184
80
945
47
387
58
688
Case Management Agency
251B00000X [38004193]
4.0e-01
4.0e-01
6.4e-01
3.3e+00
3.7e-01
3.2e-01
1.4e-01
cases:57.76%
controls:47.93%
cases:50.00%
controls:40.17%
cases:25.00%
controls:14.91%
cases:12.07%
controls:0.52%
cases:21.55%
controls:15.92%
cases:50.46%
controls:42.52%
cases:67.62%
controls:64.56%
67
556
49
604
58
466
58
694
29
173
87
987
14
6
102
1154
25
184
91
972
55
480
54
649
71
694
34
381
Exposure to unspecified factor
X59 [45756412]
1.7e+00
—
—
1.0e+50
—
1.9e+00
1.4e+00
cases:8.62%
controls:1.64%
—
—
—
—
cases:9.48%
controls:0.00%
—
—
cases:5.50%
controls:0.89%
cases:9.52%
controls:2.42%
10
19
106
1141
—
—
11
0
105
1160
—
6
10
103
1119
10
26
95
1049
Otolaryngology
4 [38004449]
5.0e-01
5.1e-01
—
1.0e+50
3.1e+00
1.0e+00
8.3e-01
cases:13.79%
controls:8.88%
cases:6.03%
controls:3.71%
—
—
cases:28.45%
controls:0.00%
cases:8.62%
controls:0.43%
cases:11.01%
controls:4.25%
cases:20.95%
controls:10.33%
16
103
100
1057
7
43
109
1117
—
33
0
83
1160
10
5
106
1151
12
48
97
1081
22
111
83
964
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
1.9e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:18.95%
cases:46.67%
controls:41.86%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
214
79
915
49
450
56
625
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
1.9e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:18.95%
cases:46.67%
controls:41.86%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
214
79
915
49
450
56
625
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
1.8e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:19.04%
cases:46.67%
controls:42.14%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
215
79
914
49
453
56
622
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
1.9e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:18.95%
cases:46.67%
controls:41.86%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
214
79
915
49
450
56
625
Platelets [#/volume] in Blood
26515-7 [3007461]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
2.1e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:18.95%
cases:46.67%
controls:41.49%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
214
79
915
49
446
56
629
MCH [Entitic mass]
28539-5 [3035941]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
4.8e-01
1.9e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.22%
—
—
cases:22.41%
controls:4.15%
cases:27.52%
controls:18.95%
cases:46.67%
controls:41.86%
23
221
93
939
32
214
84
946
14
49
102
1111
—
26
48
90
1108
30
214
79
915
49
450
56
625
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
8.5e-01
1.3e+00
—
2.2e+00
6.9e-01
4.7e-01
cases:18.97%
controls:15.60%
cases:27.59%
controls:14.05%
cases:9.48%
controls:2.76%
—
—
cases:21.55%
controls:3.03%
cases:24.77%
controls:14.17%
cases:42.86%
controls:32.00%
22
181
94
979
32
163
84
997
11
32
105
1128
—
25
35
91
1121
27
160
82
969
45
344
60
731
Leukocytes [#/volume] in Blood
26464-8 [3010813]
5.0e-02
5.2e-01
1.1e+00
—
1.9e+00
5.3e-01
1.9e-01
cases:19.83%
controls:19.05%
cases:27.59%
controls:18.45%
cases:12.07%
controls:4.31%
—
—
cases:22.41%
controls:4.24%
cases:28.44%
controls:18.95%
cases:46.67%
controls:41.86%
23
221
93
939
32
214
84
946
14
50
102
1110
—
26
49
90
1107
31
214
78
915
49
450
56
625
oxazepam; oral
N05BA04 [21604569]
1.5e+00
7.9e-01
-1.0e+50
—
—
—
1.4e+00
cases:13.79%
controls:3.45%
cases:5.17%
controls:2.41%
cases:0.00%
controls:0.69%
—
—
—
—
—
—
cases:16.19%
controls:4.37%
16
40
100
1120
6
28
110
1132
0
8
116
1152
—
—
—
17
47
88
1028
propranolol; oral, parenteral
C07AA05 [21601670]
7.2e-01
1.7e+00
—
—
—
1.2e+00
1.2e+00
cases:5.17%
controls:2.59%
cases:6.90%
controls:1.38%
—
—
—
—
—
—
cases:5.50%
controls:1.77%
cases:12.38%
controls:4.09%
6
30
110
1130
8
16
108
1144
—
—
—
6
20
103
1109
13
44
92
1031
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
4.6e-01
8.2e-01
—
—
2.8e+00
9.5e-01
7.7e-01
cases:11.21%
controls:7.41%
cases:9.48%
controls:4.40%
—
—
—
—
cases:6.90%
controls:0.43%
cases:10.09%
controls:4.16%
cases:27.62%
controls:15.07%
13
86
103
1074
11
51
105
1109
—
—
8
5
108
1151
11
47
98
1082
29
162
76
913
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.57%
controls:0.56%
—
—
—
—
—
—
9
6
96
1069
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:0.47%
—
—
—
—
—
—
7
5
98
1070
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:0.47%
—
—
—
—
—
—
7
5
98
1070
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-1.8e-02
3.8e-01
1.2e+00
—
2.0e+00
6.7e-01
7.1e-01
cases:10.34%
controls:10.52%
cases:13.79%
controls:9.83%
cases:7.76%
controls:2.50%
—
—
cases:13.79%
controls:2.16%
cases:19.27%
controls:10.89%
cases:40.95%
controls:25.49%
12
122
104
1038
16
114
100
1046
9
29
107
1131
—
16
25
100
1131
21
123
88
1006
43
274
62
801
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.5e-01
1.2e+00
—
—
2.6e+00
9.7e-01
8.5e-01
cases:9.48%
controls:5.69%
cases:9.48%
controls:3.10%
—
—
—
—
cases:8.62%
controls:0.69%
cases:7.34%
controls:2.92%
cases:20.00%
controls:9.67%
11
66
105
1094
11
36
105
1124
—
—
10
8
106
1148
8
33
101
1096
21
104
84
971
Plastic And Reconstructive Surgery
24 [38004467]
—
—
—
1.0e+50
1.0e+50
2.6e+00
1.1e+00
—
—
—
—
—
—
cases:5.17%
controls:0.00%
cases:5.17%
controls:0.00%
cases:5.50%
controls:0.44%
cases:7.62%
controls:2.79%
—
—
—
6
0
110
1160
6
0
110
1156
6
5
103
1124
8
30
97
1045
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.5e+00
—
—
—
—
—
—
cases:5.17%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
110
1155
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.5e-01
1.1e+00
—
—
2.5e+00
1.0e+00
6.4e-01
cases:11.21%
controls:5.60%
cases:10.34%
controls:3.88%
—
—
—
—
cases:5.17%
controls:0.43%
cases:7.34%
controls:2.83%
cases:16.19%
controls:9.21%
13
65
103
1095
12
45
104
1115
—
—
6
5
110
1151
8
32
101
1097
17
99
88
976
Open wound of scalp
S01.0 [45592468]
2.5e+00
—
—
—
—
—
—
cases:6.03%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
109
1154
—
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
—
—
1.0e+50
2.4e+00
1.3e+00
—
—
—
—
—
—
—
—
cases:8.62%
controls:0.00%
cases:7.34%
controls:0.71%
cases:8.57%
controls:2.51%
—
—
—
—
10
0
106
1156
8
8
101
1121
9
27
96
1048
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.8e+00
1.9e+00
—
—
—
1.9e+00
2.4e+00
cases:5.17%
controls:0.86%
cases:4.31%
controls:0.69%
—
—
—
—
—
—
cases:4.59%
controls:0.71%
cases:7.62%
controls:0.74%
6
10
110
1150
5
8
111
1152
—
—
—
5
8
104
1121
8
8
97
1067
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
—
—
—
2.4e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:5.50%
controls:0.53%
cases:4.76%
controls:1.67%
—
—
—
—
—
6
6
103
1123
5
18
100
1057
Occupational therapy
R4120 [2001310234]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.47%
—
—
—
—
—
—
5
5
100
1070
clozapine; oral, parenteral
N05AH02 [21604542]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.47%
—
—
—
—
—
—
5
5
100
1070
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
1.2e-01
4.4e-01
—
—
2.3e+00
5.1e-01
4.0e-01
cases:13.79%
controls:12.41%
cases:12.07%
controls:8.10%
—
—
—
—
cases:5.17%
controls:0.52%
cases:14.68%
controls:9.39%
cases:33.33%
controls:25.12%
16
144
100
1016
14
94
102
1066
—
—
6
6
110
1150
16
106
93
1023
35
270
70
805
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
2.3e+00
—
—
—
—
—
-1.0e+50
cases:4.31%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
5
5
111
1155
—
—
—
—
—
0
7
105
1068
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.57%
controls:0.93%
—
—
—
—
—
—
9
10
96
1065
Supplier / Service Provider
OMOP5117446 [33004]
-1.7e+00
-8.1e-01
—
—
—
—
3.9e+00
cases:6.03%
controls:25.60%
cases:4.31%
controls:9.22%
—
—
—
—
—
—
—
—
cases:19.05%
controls:0.47%
7
297
109
863
5
107
111
1053
—
—
—
—
20
5
85
1070
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.4e-01
8.8e-01
1.7e+00
—
2.2e+00
7.0e-01
5.4e-01
cases:14.66%
controls:10.00%
cases:16.38%
controls:7.50%
cases:5.17%
controls:0.95%
—
—
cases:10.34%
controls:1.30%
cases:12.84%
controls:6.82%
cases:27.62%
controls:18.14%
17
116
99
1044
19
87
97
1073
6
11
110
1149
—
12
15
104
1141
14
77
95
1052
29
195
76
880
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
—
—
—
1.0e+50
2.1e+00
1.3e+00
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.00%
cases:5.50%
controls:0.71%
cases:7.62%
controls:2.23%
—
—
—
—
5
0
111
1156
6
8
103
1121
8
24
97
1051
General medical examination
Z00.0 [45585791]
1.3e+00
2.1e+00
—
—
—
1.3e+00
7.1e-01
cases:8.62%
controls:2.41%
cases:5.17%
controls:0.69%
—
—
—
—
—
—
cases:4.59%
controls:1.33%
cases:5.71%
controls:2.88%
10
28
106
1132
6
8
110
1152
—
—
—
5
15
104
1114
6
31
99
1044
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.38%
controls:1.77%
—
—
—
—
—
—
13
19
92
1056
Neurosurgery
14 [38004459]
7.5e-01
—
—
—
—
—
1.9e+00
cases:5.17%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.02%
6
29
110
1131
—
—
—
—
—
7
11
98
1064
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.52%
controls:1.58%
—
—
—
—
—
—
10
17
95
1058
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
1.0e+50
1.0e+50
—
1.9e+00
—
—
—
—
—
—
cases:4.31%
controls:0.00%
cases:6.03%
controls:0.00%
—
—
cases:16.19%
controls:2.88%
—
—
—
5
0
111
1160
7
0
109
1156
—
17
31
88
1044
General anaesthesia
WX402 [2001310806]
-1.0e+50
—
—
—
—
—
1.9e+00
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:10.48%
controls:1.77%
0
6
116
1154
—
—
—
—
—
11
19
94
1056
sertraline; oral
N06AB06 [21604714]
1.9e+00
2.2e+00
—
—
—
—
1.5e+00
cases:7.76%
controls:1.29%
cases:4.31%
controls:0.52%
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.58%
9
15
107
1145
5
6
111
1154
—
—
—
—
7
17
98
1058
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.62%
controls:1.30%
—
—
—
—
—
—
8
14
97
1061
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
7.7e-02
6.2e-01
1.2e+00
—
1.8e+00
5.8e-01
3.6e-01
cases:18.10%
controls:16.98%
cases:24.14%
controls:14.66%
cases:7.76%
controls:2.59%
—
—
cases:12.93%
controls:2.34%
cases:23.85%
controls:14.88%
cases:42.86%
controls:34.33%
21
197
95
963
28
170
88
990
9
30
107
1130
—
15
27
101
1129
26
168
83
961
45
369
60
706
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
—
1.7e+00
—
—
—
1.2e+00
8.5e-01
—
—
cases:6.90%
controls:1.29%
—
—
—
—
—
—
cases:6.42%
controls:1.95%
cases:11.43%
controls:5.21%
—
8
15
108
1145
—
—
—
7
22
102
1107
12
56
93
1019
fluoxetine; oral
N06AB03 [21604711]
1.7e+00
2.0e+00
—
—
—
—
—
cases:6.90%
controls:1.29%
cases:4.31%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
8
15
108
1145
5
7
111
1153
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
1.2e+00
—
—
—
—
1.5e+00
1.7e+00
cases:6.03%
controls:1.90%
—
—
—
—
—
—
—
—
cases:5.50%
controls:1.24%
cases:9.52%
controls:1.86%
7
22
109
1138
—
—
—
—
6
14
103
1115
10
20
95
1055
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
-1.0e+50
—
—
—
—
—
1.7e+00
cases:0.00%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:7.62%
controls:1.49%
0
17
116
1143
—
—
—
—
—
8
16
97
1059
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-6.4e-02
4.5e-01
9.9e-01
—
1.7e+00
3.8e-01
4.3e-02
cases:13.79%
controls:14.57%
cases:18.10%
controls:12.33%
cases:6.90%
controls:2.67%
—
—
cases:13.79%
controls:2.94%
cases:18.35%
controls:13.37%
cases:32.38%
controls:31.44%
16
169
100
991
21
143
95
1017
8
31
108
1129
—
16
34
100
1122
20
151
89
978
34
338
71
737
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.57%
controls:1.77%
—
—
—
—
—
—
9
19
96
1056
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.62%
controls:1.58%
—
—
—
—
—
—
8
17
97
1058
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.7e-01
3.7e-01
1.4e+00
—
1.2e+00
9.1e-01
7.1e-01
cases:30.17%
controls:22.93%
cases:16.38%
controls:11.90%
cases:6.03%
controls:1.55%
—
—
cases:6.03%
controls:1.90%
cases:26.61%
controls:12.75%
cases:47.62%
controls:30.79%
35
266
81
894
19
138
97
1022
7
18
109
1142
—
7
22
109
1134
29
144
80
985
50
331
55
744
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.0e-01
1.1e+00
—
1.0e+50
—
1.6e+00
7.4e-01
cases:6.90%
controls:3.53%
cases:7.76%
controls:2.67%
—
—
cases:5.17%
controls:0.00%
—
—
cases:11.01%
controls:2.48%
cases:15.24%
controls:7.91%
8
41
108
1119
9
31
107
1129
—
6
0
110
1160
—
12
28
97
1101
16
85
89
990
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.43%
controls:2.60%
—
—
—
—
—
—
12
28
93
1047
Anxiety disorder, unspecified
F41.9 [45542849]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.57%
controls:1.95%
—
—
—
—
—
—
9
21
96
1054
Scheduled procedure
ZXD10 [2001311387]
-1.2e-01
—
—
—
—
1.6e+00
1.5e+00
cases:5.17%
controls:5.78%
—
—
—
—
—
—
—
—
cases:4.59%
controls:0.97%
cases:15.24%
controls:3.72%
6
67
110
1093
—
—
—
—
5
11
104
1118
16
40
89
1035
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
8.0e-01
1.2e+00
—
—
—
1.5e+00
8.5e-01
cases:11.21%
controls:5.34%
cases:10.34%
controls:3.36%
—
—
—
—
—
—
cases:9.17%
controls:2.13%
cases:16.19%
controls:7.63%
13
62
103
1098
12
39
104
1121
—
—
—
10
24
99
1105
17
82
88
993
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
7.5e-01
1.3e+00
—
—
—
—
1.5e+00
cases:6.03%
controls:2.93%
cases:6.03%
controls:1.64%
—
—
—
—
—
—
—
—
cases:17.14%
controls:4.37%
7
34
109
1126
7
19
109
1141
—
—
—
—
18
47
87
1028
Pure hypercholesterolaemia
E78.01 [2000501514]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.52%
controls:2.51%
—
—
—
—
—
—
10
27
95
1048
Emergency Room and Inpatient Visit
ERIP [262]
4.6e-01
9.1e-01
—
1.0e+50
—
1.6e+00
1.3e+00
cases:4.31%
controls:2.76%
cases:5.17%
controls:2.16%
—
—
cases:6.03%
controls:0.00%
—
—
cases:5.50%
controls:1.15%
cases:19.05%
controls:5.77%
5
32
111
1128
6
25
110
1135
—
7
0
109
1160
—
6
13
103
1116
20
62
85
1013
zopiclone; oral
N05CF01 [21604654]
1.3e+00
5.3e-01
—
—
—
9.0e-01
7.9e-01
cases:17.24%
controls:5.34%
cases:5.17%
controls:3.10%
—
—
—
—
—
—
cases:8.26%
controls:3.54%
cases:13.33%
controls:6.51%
20
62
96
1098
6
36
110
1124
—
—
—
9
40
100
1089
14
70
91
1005
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.43%
controls:3.44%
—
—
—
—
—
—
12
37
93
1038
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
1.3e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:1.33%
cases:17.14%
controls:5.49%
—
—
—
—
—
5
15
104
1114
18
59
87
1016
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
8.7e-02
—
—
1.0e+50
1.0e+50
1.1e+00
1.2e+00
cases:4.31%
controls:3.97%
—
—
—
—
cases:9.48%
controls:0.00%
cases:8.62%
controls:0.00%
cases:4.59%
controls:1.51%
cases:21.90%
controls:7.44%
5
46
111
1114
—
—
11
0
105
1160
10
0
106
1156
5
17
104
1112
23
80
82
995
Inpatient Visit
IP [9201]
3.3e-01
1.9e+00
-1.0e+50
—
—
—
1.2e+00
cases:6.03%
controls:4.40%
cases:4.31%
controls:0.69%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:14.29%
controls:4.93%
7
51
109
1109
5
8
111
1152
0
5
116
1155
—
—
—
15
53
90
1022
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.2e+00
—
—
—
1.8e+00
1.2e+00
cases:12.07%
controls:4.57%
cases:8.62%
controls:2.76%
—
—
—
—
—
—
cases:5.50%
controls:0.97%
cases:17.14%
controls:6.14%
14
53
102
1107
10
32
106
1128
—
—
—
6
11
103
1118
18
66
87
1009
EKG study
11524-6 [3013512]
5.0e-01
8.7e-01
—
—
—
—
1.1e+00
cases:5.17%
controls:3.19%
cases:5.17%
controls:2.24%
—
—
—
—
—
—
—
—
cases:16.19%
controls:5.77%
6
37
110
1123
6
26
110
1134
—
—
—
—
17
62
88
1013
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
1.5e-01
1.0e+00
—
—
—
4.0e-01
2.6e-01
cases:10.34%
controls:9.05%
cases:16.38%
controls:6.47%
—
—
—
—
—
—
cases:10.09%
controls:7.00%
cases:24.76%
controls:20.28%
12
105
104
1055
19
75
97
1085
—
—
—
11
79
98
1050
26
218
79
857
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.0e-01
8.7e-01
—
—
—
4.0e-01
3.5e-01
cases:14.66%
controls:12.33%
cases:19.83%
controls:9.40%
—
—
—
—
—
—
cases:13.76%
controls:9.65%
cases:32.38%
controls:25.30%
17
143
99
1017
23
109
93
1051
—
—
—
15
109
94
1020
34
272
71
803
Orthopedic Surgery
20 [38004465]
1.5e-01
6.7e-01
—
—
—
8.4e-01
8.6e-01
cases:12.07%
controls:10.60%
cases:6.03%
controls:3.19%
—
—
—
—
—
—
cases:8.26%
controls:3.72%
cases:26.67%
controls:13.30%
14
123
102
1037
7
37
109
1123
—
—
—
9
42
100
1087
28
143
77
932
Root filling of tooth with one root canal
SGB10 [2001310388]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
0
5
116
1155
—
—
—
0
6
109
1123
—
Other primary coxarthrosis
M16.1 [45591741]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.84%
0
14
116
1146
—
—
—
—
0
5
109
1124
0
9
105
1066
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:5.95%
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
0
69
116
1091
0
18
116
1142
—
—
—
—
—
Corrosion of other parts of alimentary tract
T28.7 [45541426]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.31%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
111
1160
—
—
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
9
116
1151
—
—
—
—
0
7
109
1122
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.0e+00
—
—
1.0e+50
—
—
1.3e+00
cases:6.03%
controls:2.24%
—
—
—
—
cases:12.93%
controls:0.00%
—
—
—
—
cases:5.71%
controls:1.58%
7
26
109
1134
—
—
15
0
101
1160
—
—
6
17
99
1058
hydrocortisone aceponate
D07AC16 [21602135]
-4.0e-02
—
—
—
—
5.3e-01
-3.4e-02
cases:6.90%
controls:7.16%
—
—
—
—
—
—
—
—
cases:4.59%
controls:2.75%
cases:6.67%
controls:6.88%
8
83
108
1077
—
—
—
—
5
31
104
1098
7
74
98
1001
nystatin; oral
A07AA02 [21600604]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
10
105
1065
Polyuria
R35 [45539331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
bisoprolol and thiazides
C07BB07 [21601714]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
0
6
116
1154
—
—
—
—
0
6
109
1123
—
Severe psychotic and other severe mental disorders
112 [2001600112]
1.9e+00
—
—
—
—
—
—
cases:5.17%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
6
9
110
1151
—
—
—
—
—
—
Calculus of ureter
N20.1 [45582395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Kolposcopy
ULA02 [2001306679]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
8
109
1121
—
Insulin-dependent diabetes mellitus - Diabetic retinopathy
H36.09*E10.3 [2000502327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Alcoholic cirrhosis of liver
K70.3 [45596343]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
Spinalanesthesia
WX320 [2001310799]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
27
116
1133
—
—
—
—
—
—
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
—
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:5.00%
—
—
cases:0.00%
controls:1.21%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
0
58
116
1102
—
0
14
116
1146
—
0
9
116
1147
—
—
mometasone; nasal
R01AD09 [21605051]
3.4e-01
—
—
—
—
6.2e-01
4.2e-01
cases:10.34%
controls:7.59%
—
—
—
—
—
—
—
—
cases:6.42%
controls:3.54%
cases:12.38%
controls:8.47%
12
88
104
1072
—
—
—
—
7
40
102
1089
13
91
92
984
naproxcinod
M01AE18 [40254094]
7.6e-01
7.1e-01
-1.0e+50
—
—
6.3e-01
6.6e-01
cases:18.10%
controls:9.40%
cases:4.31%
controls:2.16%
cases:0.00%
controls:0.43%
—
—
—
—
cases:5.50%
controls:3.01%
cases:14.29%
controls:7.91%
21
109
95
1051
5
25
111
1135
0
5
116
1155
—
—
6
34
103
1095
15
85
90
990
hepatitis B, purified antigen
J07BC01 [21601338]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.65%
0
7
116
1153
—
—
—
—
0
6
109
1123
0
7
105
1068
insulin aspart; parenteral
A10AB05 [21600719]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:4.48%
cases:0.00%
controls:4.31%
cases:0.00%
controls:0.95%
—
—
cases:0.00%
controls:0.69%
cases:0.00%
controls:4.07%
—
—
0
52
116
1108
0
50
116
1110
0
11
116
1149
—
0
8
116
1148
0
46
109
1083
—
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
105
1067
Malignant tumour
130 [2001600128]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
5
116
1155
—
—
—
—
—
0
7
105
1068
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
Fibromyalgia
M79.7 [45553272]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Diarrhoea
D11 [2002000310]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
5
109
1124
—
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:2.14%
—
—
—
—
—
—
6
23
99
1052
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
6.9e-01
—
—
—
—
—
6.3e-01
cases:5.17%
controls:2.67%
—
—
—
—
—
—
—
—
—
—
cases:11.43%
controls:6.42%
6
31
110
1129
—
—
—
—
—
12
69
93
1006
Naevus/mole
S82 [2002001046]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.56%
—
—
—
—
—
0
5
109
1124
0
6
105
1069
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
FNA01 [2001303015]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:0.89%
—
—
—
—
—
—
—
5
10
104
1119
—
opium derivatives and expectorants
R05FA02 [21603439]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.74%
0
9
116
1151
—
—
—
—
0
6
109
1123
0
8
105
1067
norfloxacin; oral
J01MA06 [21603013]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.02%
—
—
—
—
—
—
5
11
100
1064
Gynaecological examination
SPAT1192 [2001700293]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
8
109
1121
—
Hand/finger symptom/complaint
L12 [2002000636]
-1.0e+50
—
—
—
—
—
1.3e+00
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.30%
0
16
116
1144
—
—
—
—
—
5
14
100
1061
ranitidine bismuth citrate; oral
A02BA07 [21600088]
5.3e-01
—
—
—
—
—
—
cases:4.31%
controls:2.59%
—
—
—
—
—
—
—
—
—
—
—
—
5
30
111
1130
—
—
—
—
—
—
sodium fluoride; oral
A01AA01 [21600005]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
—
prednisolone
S01BA04 [21603621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
116
1149
—
—
—
—
—
—
loperamide oxide; oral
A07DA05 [21600648]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.74%
—
—
—
—
—
—
5
8
100
1067
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:2.05%
—
—
—
—
—
0
9
109
1120
0
22
105
1053
Other angina pectoris unspecified coronary artery status
I20.89 [2000502401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Limited function/disability NOS
A28 [2002000162]
1.2e+00
—
—
—
—
1.5e+00
1.3e+00
cases:4.31%
controls:1.29%
—
—
—
—
—
—
—
—
cases:4.59%
controls:1.06%
cases:6.67%
controls:1.95%
5
15
111
1145
—
—
—
—
5
12
104
1117
7
21
98
1054
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.4e-02
5.9e-01
—
—
—
—
5.0e-01
cases:5.17%
controls:4.91%
cases:6.03%
controls:3.45%
—
—
—
—
—
—
—
—
cases:19.05%
controls:12.47%
6
57
110
1103
7
40
109
1120
—
—
—
—
20
134
85
941
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
almotriptan; oral
N02CC05 [21604380]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.74%
—
—
—
—
—
0
5
109
1124
0
8
105
1067
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.02%
0
5
116
1155
—
—
—
—
0
7
109
1122
0
11
105
1064
Treatment plan or consultation
WZC00 [2001310885]
-6.1e-02
-1.0e+50
—
—
—
—
5.1e-01
cases:4.31%
controls:4.57%
cases:0.00%
controls:1.47%
—
—
—
—
—
—
—
—
cases:9.52%
controls:5.95%
5
53
111
1107
0
17
116
1143
—
—
—
—
10
64
95
1011
Chronic ischaemic heart disease
I25 [45581765]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
Cough
R05 [2002000886]
—
—
—
—
—
-1.0e+50
4.0e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.76%
controls:3.26%
—
—
—
—
—
0
8
109
1121
5
35
100
1040
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
7
109
1122
—
pH of Urine
2756-5 [3015736]
1.6e-01
6.5e-01
—
—
—
—
5.1e-01
cases:4.31%
controls:3.71%
cases:5.17%
controls:2.76%
—
—
—
—
—
—
—
—
cases:15.24%
controls:9.77%
5
43
111
1117
6
32
110
1128
—
—
—
—
16
105
89
970
fusidic acid
D09AA02 [21602265]
4.6e-01
—
—
—
—
-1.0e+50
—
cases:4.31%
controls:2.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
5
32
111
1128
—
—
—
—
0
15
109
1114
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
116
1150
—
—
—
—
—
—
Sick sinus syndrome
I49.5 [45562354]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
Primary total prosthetic replacement of knee joint without patellar part
NGB20 [2001308094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
cough suppressants and mucolytics
R05FB01 [21603441]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
1.0e+50
—
—
1.2e+00
—
—
—
—
—
—
cases:4.31%
controls:0.00%
—
—
—
—
cases:5.71%
controls:1.86%
—
—
—
5
0
111
1160
—
—
6
20
99
1055
finasteride; oral
D11AX10 [21602350]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.98%
cases:0.00%
controls:1.29%
—
—
—
—
—
—
cases:0.00%
controls:1.33%
—
—
0
23
116
1137
0
15
116
1145
—
—
—
0
15
109
1114
—
Exposure to other specified factors
X58 [45756411]
1.1e+00
—
—
1.0e+50
—
—
1.2e+00
cases:4.31%
controls:1.47%
—
—
—
—
cases:6.03%
controls:0.00%
—
—
—
—
cases:6.67%
controls:2.14%
5
17
111
1143
—
—
7
0
109
1160
—
—
7
23
98
1052
Periodic check-up in occupational healthcare
SPAT1368 [2001700469]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
5
116
1155
—
—
—
—
—
0
5
105
1070
Custom moulded cast, unspecified region
TNX33 [2001308564]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
5
116
1155
—
—
—
—
—
0
6
105
1069
Other hypothyroidism
E03 [45581337]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
loperamide; oral
A07DA03 [21600646]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.74%
—
—
—
—
—
—
5
8
100
1067
Other minor procedure on skin
TQW99 [2001310150]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Transurethral resection of prostate
KED22 [2001306138]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
1.0e+00
—
—
—
—
—
6.8e-01
cases:6.03%
controls:2.24%
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:2.98%
7
26
109
1134
—
—
—
—
—
6
32
99
1043
Pain in thoracic spine
M54.6 [45606247]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
105
1067
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.40%
—
—
—
—
—
—
5
15
100
1060
Chronic hypertension
205 [2001600203]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.58%
—
—
—
—
—
—
5
17
100
1058
Knee and lower leg MRI examination with high intensity magnet
NG1BG [2001308056]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
—
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
—
—
—
—
—
—
3.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:4.19%
—
—
—
—
—
—
6
45
99
1030
cyproterone and estrogen
G03HB01 [21602617]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:1.40%
—
—
—
—
—
—
6
15
99
1060
Migraine without aura [common migraine]
G43.0 [45600784]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
6
116
1154
—
—
—
—
—
0
5
105
1070
oxycodone and naloxone; oral
N02AA55 [21604265]
—
-1.0e+50
—
—
—
-1.0e+50
9.2e-01
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.76%
controls:1.95%
—
0
6
116
1154
—
—
—
0
8
109
1121
5
21
100
1054
Removal of sutures from oral mucosa
SXB00 [2001310580]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
5
116
1155
0
5
116
1155
—
—
—
0
7
109
1122
—
risperidone; oral, parenteral
N05AX08 [21604559]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.30%
—
—
—
—
—
—
7
14
98
1061
Assistance to normal delivery
MAX99 [2001306918]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
11
105
1064
Stomach Pathology biopsy report
66114-0 [40768797]
-1.0e+50
—
—
—
—
—
7.4e-01
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:2.33%
0
14
116
1146
—
—
—
—
—
5
25
100
1050
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
-1.0e+50
8.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.76%
controls:2.14%
—
—
—
—
—
0
8
109
1121
5
23
100
1052
Bacteria identified in Stool by Culture
625-4 [3025941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
0
15
105
1060
Two-surface restoration
SFA20 [2001310359]
-2.5e-01
7.3e-01
—
—
-1.0e+50
9.1e-02
-6.7e-02
cases:8.62%
controls:10.78%
cases:10.34%
controls:5.26%
—
—
—
—
cases:0.00%
controls:0.69%
cases:5.50%
controls:5.05%
cases:16.19%
controls:17.12%
10
125
106
1035
12
61
104
1099
—
—
0
8
116
1148
6
57
103
1072
17
184
88
891
Anoscopy
UJH02 [2001305182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
ivermectin
D11AX22 [45893486]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
hydrocortisone and antiinfectives
S02CA03 [21605175]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.47%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.58%
0
17
116
1143
0
5
116
1155
—
—
—
0
7
109
1122
0
17
105
1058
Nursing episode
950 [44777714]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
5
109
1124
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
3.6e-01
—
—
—
—
-1.0e+50
2.8e-01
cases:6.90%
controls:4.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.24%
cases:6.67%
controls:5.12%
8
57
108
1103
—
—
—
—
0
14
109
1115
7
55
98
1020
Ear symptom/complaint other
H29 [2002000484]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.49%
—
—
—
—
—
—
0
16
105
1059
Conjunctival surface anesthesia
WX100 [2001310764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
Conjunctivitis
H10 [45581570]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
Complicated extraction of tooth
EBA05 [2001301924]
8.9e-01
—
—
—
—
-1.0e+50
5.5e-01
cases:4.31%
controls:1.81%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.76%
controls:2.79%
5
21
111
1139
—
—
—
—
0
8
109
1121
5
30
100
1045
Helicobacter pylori Ab [Presence] in Serum
22310-7 [3038177]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
105
1068
Basophils [#/volume] in Blood
26444-0 [3006315]
3.4e-01
8.6e-01
—
—
—
—
6.1e-01
cases:6.90%
controls:5.00%
cases:7.76%
controls:3.45%
—
—
—
—
—
—
—
—
cases:19.05%
controls:11.35%
8
58
108
1102
9
40
107
1120
—
—
—
—
20
122
85
953
glucosamine; oral
M01AX05 [21604002]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
0
11
116
1149
—
—
—
—
—
Atrial fibrillation/flutter
K78 [2002000605]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
105
1068
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
9.9e-01
—
—
—
—
6.9e-01
—
—
cases:4.31%
controls:1.64%
—
—
—
—
—
—
—
—
cases:12.38%
controls:6.60%
—
5
19
111
1141
—
—
—
—
13
71
92
1004
Audiometric test
21727005 [4071702]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
15
116
1145
—
—
—
—
0
7
109
1122
—
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
5.3e-01
cases:0.00%
controls:3.71%
cases:0.00%
controls:1.21%
—
—
—
—
—
—
cases:0.00%
controls:1.95%
cases:9.52%
controls:5.86%
0
43
116
1117
0
14
116
1146
—
—
—
0
22
109
1107
10
63
95
1012
Actinic keratosis
L57.0 [45591640]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.69%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
0
8
116
1152
0
5
116
1155
—
—
—
—
0
9
105
1066
Telehealth
OMOP5556618 [722455]
-1.5e-01
6.0e-01
—
—
—
3.6e-01
1.1e-01
cases:15.52%
controls:17.59%
cases:14.66%
controls:8.62%
—
—
—
—
—
—
cases:12.84%
controls:9.30%
cases:24.76%
controls:22.70%
18
204
98
956
17
100
99
1060
—
—
—
14
105
95
1024
26
244
79
831
Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
32166-1 [3008714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
9
105
1066
simvastatin; oral
C10AA01 [21601856]
-1.2e-01
-3.5e-01
—
—
-1.0e+50
-1.2e-01
2.8e-01
cases:8.62%
controls:9.66%
cases:5.17%
controls:7.16%
—
—
—
—
cases:0.00%
controls:1.64%
cases:6.42%
controls:7.17%
cases:12.38%
controls:9.67%
10
112
106
1048
6
83
110
1077
—
—
0
19
116
1137
7
81
102
1048
13
104
92
971
furosemide; oral, parenteral
C03CA01 [21601518]
-1.6e-01
—
—
—
—
—
—
cases:4.31%
controls:5.00%
—
—
—
—
—
—
—
—
—
—
—
—
5
58
111
1102
—
—
—
—
—
—
metformin; oral
A10BA02 [21600747]
-1.5e-02
-2.4e-01
—
—
—
—
1.9e-01
cases:6.03%
controls:6.12%
cases:4.31%
controls:5.43%
—
—
—
—
—
—
—
—
cases:9.52%
controls:8.00%
7
71
109
1089
5
63
111
1097
—
—
—
—
10
86
95
989
Hyperlipidaemia, unspecified
E78.5 [45537986]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
6
109
1123
—
norethisterone; oral
G03DC02 [21602553]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
0
6
116
1154
—
—
—
0
8
109
1121
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
6.0e-01
1.5e+00
—
—
—
—
—
cases:4.31%
controls:2.41%
cases:4.31%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
5
28
111
1132
5
12
111
1148
—
—
—
—
—
Mixed asthma
J45.8 [45548118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
—
—
—
—
—
—
Subjective visual disturbances
H53.1 [45557467]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
116
1152
—
—
—
—
—
—
hydrocortisone
S02BA01 [21605166]
1.3e-01
—
—
—
—
7.5e-01
—
cases:6.90%
controls:6.12%
—
—
—
—
—
—
—
—
cases:4.59%
controls:2.21%
—
—
8
71
108
1089
—
—
—
—
5
25
104
1104
—
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
116
1148
—
—
—
—
—
—
lisinopril; oral
C09AA03 [21601787]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
7
109
1122
—
linagliptin; oral
A10BH05 [40251691]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
105
1068
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
8
105
1067
Endoscopic polypectomy in colon
JFA15 [2001304850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Protein C actual/normal in Platelet poor plasma by Coagulation assay
27819-2 [3020287]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Basophils/Leukocytes in Blood
30180-4 [3022096]
4.2e-01
1.1e+00
—
—
—
—
6.9e-01
cases:6.90%
controls:4.66%
cases:8.62%
controls:3.19%
—
—
—
—
—
—
—
—
cases:20.00%
controls:11.16%
8
54
108
1106
10
37
106
1123
—
—
—
—
21
120
84
955
ECG with 12 standard connections
XF400 [2001303368]
9.9e-01
—
—
1.0e+50
—
-1.0e+50
1.4e+00
cases:4.31%
controls:1.64%
—
—
—
—
cases:4.31%
controls:0.00%
—
—
cases:0.00%
controls:0.71%
cases:4.76%
controls:1.21%
5
19
111
1141
—
—
5
0
111
1160
—
0
8
109
1121
5
13
100
1062
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
9
105
1066
Foot/toe symptom/complaint
L17 [2002000641]
4.9e-01
—
—
—
—
-1.0e+50
3.0e-01
cases:4.31%
controls:2.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:6.67%
controls:5.02%
5
31
111
1129
—
—
—
—
0
13
109
1116
7
54
98
1021
aripiprazole; oral, parenteral
N05AX12 [21604562]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:1.67%
—
—
—
—
—
—
6
18
99
1057
Radiotherapy after partial ablation of mammary gland
HA003 [2001303965]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Acute maxillary sinusitis
J01.0 [45601112]
9.5e-01
—
—
—
—
-1.0e+50
—
cases:6.03%
controls:2.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
7
28
109
1132
—
—
—
—
0
7
109
1122
—
Specialty-specific consultation based on referral by dentist or doctor
WZC05 [2001310886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
116
1151
—
—
—
—
—
—
Corneal ulcer
H16.0 [45557339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Handing over of treatment supplies
SPAT1262 [2001700363]
—
—
-1.0e+50
—
—
—
-1.8e-01
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
cases:4.76%
controls:5.67%
—
—
0
8
116
1152
—
—
—
5
61
100
1014
Ear microscopy
UDC00 [2001301558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
atorvastatin; oral
C10AA05 [21601860]
1.7e-01
2.0e-01
1.1e+00
—
—
2.2e-02
1.7e-03
cases:7.76%
controls:6.64%
cases:7.76%
controls:6.47%
cases:4.31%
controls:1.47%
—
—
—
—
cases:6.42%
controls:6.29%
cases:8.57%
controls:8.56%
9
77
107
1083
9
75
107
1085
5
17
111
1143
—
—
7
71
102
1058
9
92
96
983
nifedipine; oral, parenteral
C08CA05 [21601751]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
10
116
1150
0
5
116
1155
—
—
—
—
0
6
105
1069
Person consulting for explanation of investigation findings
Z71.2 [45552100]
—
-1.0e+50
—
—
—
-1.0e+50
3.7e-01
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
cases:0.00%
controls:0.89%
cases:4.76%
controls:3.35%
—
0
12
116
1148
—
—
—
0
10
109
1119
5
36
100
1039
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.71%
controls:1.21%
—
—
—
—
—
—
6
13
99
1062
Medical examin/health eval partial
-31 [2002000102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
116
1152
—
—
—
—
—
—
latanoprost
S01EE01 [21603710]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
celecoxib
L01XX33 [21603805]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
2.4e-01
—
—
—
—
—
5.2e-01
cases:18.97%
controls:15.52%
—
—
—
—
—
—
—
—
—
—
cases:20.95%
controls:13.58%
22
180
94
980
—
—
—
—
—
22
146
83
929
Tinea pedis
B35.3 [45581158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Pregnancy
W78 [2002001269]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
6
116
1154
0
7
116
1153
—
—
—
—
—
Chondromalacia patellae
M22.4 [45538712]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
etodolac; oral
M01AB08 [21603948]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.30%
0
6
116
1154
0
7
116
1153
—
—
—
0
7
109
1122
0
14
105
1061
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
116
1149
—
—
—
—
—
—
clonazepam; oral, parenteral
N03AE01 [21604415]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.74%
—
—
—
—
—
—
5
8
100
1067
Pollen allergy UNS
J30.19 [2000502595]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
Protein [Mass/volume] in Urine
2888-6 [3037121]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
116
1153
—
—
—
—
—
—
tretinoin; ointment
D10AD01 [21602293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
0
9
105
1066
Unspecified lump in breast
N63 [45601743]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
3.2e-01
—
—
—
—
—
5.8e-01
cases:6.90%
controls:5.09%
—
—
—
—
—
—
—
—
—
—
cases:12.38%
controls:7.35%
8
59
108
1101
—
—
—
—
—
13
79
92
996
Hand Surgery
40 [38004480]
7.1e-01
—
—
—
—
—
1.2e+00
cases:4.31%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:2.05%
5
25
111
1135
—
—
—
—
—
7
22
98
1053
Routine general health check-up of other defined subpopulations
Z10.8 [45609907]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
116
1147
—
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
116
1146
—
—
—
—
—
—
solifenacin; oral
G04BD08 [21602641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
116
1152
—
—
—
—
—
—
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
12 lead EKG panel
34534-8 [3044889]
1.0e-02
8.0e-01
—
—
—
7.2e-01
6.1e-01
cases:9.48%
controls:9.40%
cases:10.34%
controls:4.91%
—
—
—
—
—
—
cases:11.01%
controls:5.67%
cases:26.67%
controls:16.56%
11
109
105
1051
12
57
104
1103
—
—
—
12
64
97
1065
28
178
77
897
Dizziness and giddiness
R42 [45568132]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:7.62%
controls:2.70%
—
0
10
116
1150
—
—
—
—
8
29
97
1046
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
—
-1.0e+50
—
—
—
—
-3.6e-02
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.76%
controls:4.93%
—
0
11
116
1149
—
—
—
—
5
53
100
1022
Provision of support and information to patient’s family members
SPAT1245 [2001700346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Boil/carbuncle
S10 [2002000975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Blood transfusion
WW500 [2001310603]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
Type 2 diabetes mellitus, with ophthalmic complications
E11.3 [45591028]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
6
116
1154
—
—
—
—
—
0
6
105
1069
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
6
109
1123
—
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
prednisone; oral
H02AB07 [21602735]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
6
109
1123
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.57%
controls:5.30%
—
—
—
—
—
—
9
57
96
1018
Recording of ECG
SPAT1097 [2001700198]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:5.71%
controls:1.77%
—
0
8
116
1152
—
—
—
0
9
109
1120
6
19
99
1056
amlodipine; oral
C08CA01 [21601747]
-3.8e-01
—
—
—
—
—
2.7e-01
cases:4.31%
controls:6.21%
—
—
—
—
—
—
—
—
—
—
cases:10.48%
controls:8.19%
5
72
111
1088
—
—
—
—
—
11
88
94
987
Spondylolisthesis
M43.1 [45606219]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
7
105
1068
Monitoring the use of the aid
R5140 [2001310249]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
116
1149
—
—
—
—
—
—
Difficulties in perfomrming procedure
ZXD30 [2001311389]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
0
6
116
1154
—
—
—
—
—
0
6
105
1069
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
116
1147
—
—
—
—
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
1.1e+00
1.1e+00
—
—
—
—
9.6e-01
cases:8.62%
controls:3.02%
cases:4.31%
controls:1.47%
—
—
—
—
—
—
—
—
cases:16.19%
controls:6.88%
10
35
106
1125
5
17
111
1143
—
—
—
—
17
74
88
1001
Diabetic background retinopathy
H36.00 [2000502320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
5
105
1070
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
—
3.9e-01
4.5e-01
—
—
—
—
—
—
—
—
—
—
cases:5.50%
controls:3.81%
cases:6.67%
controls:4.37%
—
—
—
—
—
6
43
103
1086
7
47
98
1028
salmeterol and fluticasone
R03AK06 [21603280]
7.6e-01
—
—
—
-1.0e+50
—
1.0e+00
cases:4.31%
controls:2.07%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
cases:5.71%
controls:2.14%
5
24
111
1136
—
—
—
0
6
116
1150
—
6
23
99
1052
Swelling
A08 [2002000149]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
6
105
1069
telmisartan and diuretics
C09DA07 [21601839]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
116
1155
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.49%
0
6
116
1154
—
—
—
—
—
0
16
105
1059
Asthma
J45 [45596282]
9.4e-01
—
—
—
—
—
—
cases:4.31%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
—
—
5
20
111
1140
—
—
—
—
—
—
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.78%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
9
116
1151
0
5
116
1155
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
55
233
3.51
10.28
6.2
4.5
—
—
—
0
0
38
137
3.60
8.96
1.9
1.7
988.55
1235.61
nmol/l
1.14
33
101
89
565
3.23
7.57
11.6
5.5
6.31
6.56
mmol/l
0.76
84
531
28
92
3.67
7.48
10.3
14.0
2.90
0.52
mmol/l
1.85
23
83
27
94
3.42
6.57
10.8
13.8
7.40
7.42
ph
0.69
19
62
55
295
2.60
6.06
6.3
2.3
—
—
—
0
0
70
424
2.56
5.94
15.1
14.3
1.15
1.20
inr
0.59
61
355
27
103
3.09
5.62
10.4
8.1
103.19
104.31
mmol/l
0.50
27
103
17
48
3.96
5.56
9.1
11.6
26.07
23.74
mmol/l
1.19
17
48
43
221
2.47
5.02
1.6
1.6
1.37
1.40
mg/l
0.02
36
174
69
438
2.35
4.99
5.6
2.8
—
—
estimate
—
0
0
19
65
3.28
4.69
9.8
9.6
1.20
1.46
mmol/l
0.47
19
65
47
261
2.32
4.55
4.0
4.1
7.40
7.40
ph
0.38
38
187
23
90
2.92
4.54
4.3
2.4
0.19
0.23
g/l
1.53
23
82
16
50
3.54
4.52
5.4
12.8
—
—
—
0
0
60
370
2.24
4.52
2.5
2.0
95.94
97.50
pmol/l
0.10
42
194
14
41
3.73
4.33
2.7
2.3
—
—
—
0
0
11
25
4.73
3.73
7.7
3.3
7.41
7.41
ph
0.10
11
25
24
110
2.48
3.48
3.5
1.6
—
—
—
0
0
14
48
3.17
3.43
5.9
6.6
26.86
23.98
mmol/l
1.26
14
48
14
48
3.17
3.43
12.6
11.7
0.76
0.67
%
0.30
14
48
17
66
2.84
3.38
10.6
10.1
—
—
—
0
0
57
375
1.99
3.36
6.1
3.5
59.79
30.99
ng/l
0.35
44
242
26
126
2.36
3.34
3.9
2.5
—
—
—
0
0
6
8
7.82
3.09
13.7
10.6
0.65
0.45
mmol/l
—
6
8
14
52
2.92
3.01
12.6
10.6
1.74
1.51
%
0.24
14
52
17
72
2.59
2.88
12.5
2.7
—
—
—
0
0
12
43
2.99
2.73
1.6
2.7
28.05
24.05
mmol/l
2.08
12
43
17
74
2.51
2.73
12.5
2.1
—
—
—
0
0
49
325
1.86
2.69
8.3
5.4
—
—
—
0
0
15
62
2.62
2.66
1.6
1.5
0.28
0.30
mg/l
—
8
31
27
147
2.08
2.60
1.9
1.8
—
—
—
0
0
17
76
2.44
2.58
2.2
4.0
7.38
7.39
ph
0.13
12
46
5
7
7.39
2.57
1.4
1.0
4.38
5.97
mmol/l
—
5
7
16
71
2.45
2.47
13.2
2.6
—
—
—
0
0
20
101
2.18
2.32
1.9
1.8
—
—
—
0
0
7
18
4.06
2.29
9.1
2.6
9.34
8.50
kpa
—
7
18
7
18
4.06
2.29
9.1
2.6
5.00
4.89
kpa
—
7
18
24
133
2.01
2.20
1.5
1.3
—
—
—
0
0
16
76
2.28
2.14
13.3
2.5
—
—
—
0
0
16
76
2.28
2.14
13.3
2.5
—
—
—
0
0
21
112
2.06
2.13
2.1
1.7
—
—
—
0
0
9
32
2.96
2.05
16.7
3.8
—
—
—
0
0
106
933
2.17
2.01
6.2
5.6
37.71
38.79
mmol/mol
0.61
101
881
7
21
3.47
2.00
5.4
2.0
3.77
3.94
mmol/l
—
7
21
39
269
1.67
1.76
3.9
2.7
—
—
—
0
0
17
90
2.04
1.76
3.5
5.0
0.00
0.29
%
—
6
21
6
19
3.27
1.68
4.5
3.4
—
—
—
0
0
5
14
3.68
1.63
2.8
1.8
—
—
—
0
0
5
15
3.43
1.54
7.4
1.5
93.22
92.21
%
—
5
15
5
15
3.43
1.54
2.2
1.9
12.40
10.26
mmol/l
—
5
15
31
210
1.64
1.48
1.9
1.8
—
—
—
0
0
5
16
3.21
1.45
7.8
1.7
1.66
1.57
mmol/l
—
5
16
42
308
1.56
1.45
1.7
1.5
—
—
—
0
0
42
310
1.55
1.40
4.6
3.8
0.00
0.02
estimate
0.50
15
115
82
700
1.54
1.37
5.9
4.2
—
—
—
0
0
60
483
1.48
1.31
2.9
2.8
113.01
105.33
ug/l
0.16
55
450
37
271
1.53
1.26
2.2
2.2
—
—
—
0
0
13
71
1.93
1.25
2.2
3.3
71.35
73.52
e9/l
—
8
49
16
94
1.81
1.25
2.9
5.5
0.00
0.38
%
—
5
21
16
94
1.81
1.25
3.7
4.9
0.17
0.92
%
—
6
26
26
176
1.61
1.24
6.1
2.9
802.70
107.33
ng/l
0.41
20
122
5
19
2.70
1.23
1.0
1.0
—
—
—
0
0
5
19
2.70
1.23
7.8
3.2
17.80
17.18
%
—
5
19
15
87
1.83
1.22
3.8
5.1
0.33
0.61
%
—
6
23
71
597
1.46
1.21
18.7
9.2
4.21
4.02
e9/l
0.24
65
531
5
21
2.44
1.10
1.0
1.1
—
—
—
0
0
5
22
2.33
1.04
18.2
7.2
—
—
—
0
0
13
76
1.80
1.03
6.5
4.2
1.21
1.22
mmol/l
0.34
13
62
0
30
0.00
0.99
0.0
1.2
—
—
—
0
0
66
563
1.38
0.96
4.7
3.7
83.94
0.00
estimate
0.48
16
122
34
260
1.43
0.92
6.7
3.7
1.02
1.02
kg/l
0.11
27
181
14
87
1.69
0.92
1.1
1.1
—
—
—
0
0
43
344
1.39
0.91
3.8
3.0
0.00
0.00
estimate
-0.00
11
95
109
1023
1.71
0.90
37.2
13.0
20.73
22.00
mg/l
0.22
98
828
6
30
2.05
0.88
1.3
2.6
26.50
25.34
mmol/l
—
6
30
8
45
1.83
0.86
2.9
1.8
—
—
—
0
0
40
324
1.35
0.77
3.6
3.1
16.36
234.96
e6/l
0.60
31
259
34
269
1.37
0.76
1.4
1.3
0.87
0.87
u/ml
0.00
12
79
9
55
1.69
0.75
1.2
1.3
—
—
—
0
0
111
1055
1.69
0.75
34.1
12.6
—
—
—
0
0
53
450
1.32
0.74
4.5
3.4
0.00
0.04
estimate
0.68
14
102
5
26
1.96
0.71
1.0
1.1
458.00
449.23
mg/l
—
5
26
5
26
1.96
0.71
1.0
1.3
—
—
—
0
0
65
571
1.30
0.70
5.0
3.7
0.00
0.00
estimate
-0.00
16
114
7
43
1.67
0.68
4.1
2.9
0.79
0.71
%
—
7
43
41
340
1.31
0.67
5.6
3.4
9.57
8.69
mmol/l
0.36
35
298
52
447
1.29
0.65
4.9
3.4
6.43
6.17
ph
0.99
35
272
0
20
0.00
0.61
0.0
3.6
—
49.90
—
0
20
11
160
0.66
0.60
1.4
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.8
—
—
—
0
0
44
375
1.27
0.58
4.2
3.7
14.90
57.51
e6/l
1.14
31
275
37
310
1.28
0.55
9.6
5.1
—
—
—
0
0
7
47
1.52
0.48
1.9
2.6
—
0.00
estimate
—
0
19
24
193
1.30
0.48
3.6
2.5
469.62
548.49
mosm/kgh2o
1.16
24
171
62
559
1.23
0.48
4.6
3.7
0.00
0.00
estimate
-0.00
16
120
41
464
0.82
0.41
3.2
3.0
—
—
—
0
0
51
456
1.21
0.41
25.0
11.4
0.00
0.00
e9/l
0.71
45
380
5
34
1.49
0.41
2.4
2.6
—
—
—
0
0
17
212
0.77
0.40
2.7
2.7
0.69
0.77
ug/l
—
9
110
32
275
1.22
0.38
3.6
2.8
0.75
0.30
e6/l
0.41
24
211
111
1075
1.43
0.37
39.0
17.1
71.72
76.51
umol/l
1.67
111
1062
101
971
1.25
0.34
6.4
4.6
5.89
5.83
mmol/l
0.14
96
908
43
387
1.17
0.31
1.8
2.0
—
—
—
0
0
28
243
1.20
0.30
3.6
2.7
7.52
5.83
e6/l
0.36
28
225
14
169
0.81
0.26
1.6
1.9
—
—
—
0
0
24
272
0.85
0.24
5.9
4.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
6
47
1.29
0.21
1.5
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
98
954
1.15
0.18
5.0
4.1
1.50
1.32
mmol/l
1.14
92
898
102
998
1.15
0.15
5.1
4.8
1.39
1.43
mmol/l
0.41
97
941
10
114
0.87
0.10
1.5
1.2
—
—
—
0
0
7
67
1.05
0.08
1.0
1.2
—
—
—
0
0
25
237
1.07
0.06
1.5
1.4
2.10
2.72
g/l
0.69
17
147
11
121
0.90
0.06
1.4
1.4
—
—
—
0
0
29
303
0.94
0.06
2.8
4.2
2.31
9.44
mg/mmol
2.60
19
203
29
301
0.95
0.04
2.9
3.4
242.45
63.98
mg/l
0.37
19
204
11
113
0.97
0.00
1.2
1.5
—
—
—
0
0
18
183
0.98
0.00
1.6
1.4
5.42
6.96
u/ml
—
6
71
10
95
1.06
0.00
5.1
3.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
1.00
—
0
6
8
82
0.97
-0.00
1.8
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
125.60
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
58.20
—
0
5
0
7
0.00
-0.00
0.0
10.6
—
15.93
—
0
7
0
6
0.00
-0.00
0.0
2.8
—
2.92
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
280.67
—
0
6
0
6
0.00
-0.00
0.0
2.8
—
5.73
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
1.80
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
9.57
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
69.00
—
0
5
0
8
0.00
-0.00
0.0
3.9
—
10.18
—
0
8

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: ST19_BURN_CORROSION_OTHER_INTERNAL_ORGANS – Burn and corrosion of other internal organs

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).